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Understanding of how persistent viral infection impacts humoral immunity is incomplete. In this issue of
Immunity, Wieland et al. (2015) and Yamada et al. (2015) find that high amounts of IgG-antigen complexes
formed during chronic lymphocytic choriomeningitis infection can interfere with Fcg-receptor-mediated
effector activities, potentially contributing to immune dysfunction.Immune complexes (ICs) typically form
when polyclonal antibodies bind to poly-
valent antigens forming large antibody-an-
tigen complexes. While IC formation is an
inevitable consequence of an effective im-
mune response and is required for clear-
ance of pathogenic antigens, inappro-
priate generation and deposition of such
complexes results in pathology (Couser
and Salant, 1980). Thus, the generation
and clearance of immune complexes is a
tightly regulated process; perturbations in
immune complex clearance are associ-
ated with a variety of disease states due
to activation of innate and adaptive im-
mune cells within lymphoid organs or at
a site of infection through crosslinking
of Fcg receptors (FcgR). In this issue of
Immunity, papers by Weiland et al. and
Yamada et al. describe a phenomenon
whereby high amounts of IC formed during
chronic lymphocytic choriomeningitis
(LCMV) infection did not cause inflamma-
tory disease due to crosslinking of FcgRs;
instead, the IC were found to interfere with
immunoglobulin G (IgG)-mediated effector
functions by blocking FcgR interactions.
In the healthy host, IC production oc-
curs in response to acute events such as
infection, effectively restricting inflamma-
tory signaling to instances warranting anactive immune response. Cellular func-
tions involved in clearing infection are, in
part, mediated through FcgRs and in-
clude phagocytosis, antibody-dependent
cell cytotoxicity (ADCC), antigen presen-
tation, and selection of B cells during anti-
body responses (Pincetic et al., 2014).
Following resolution of an infection, ICs
are no longer generated and existing ICs
are rapidly cleared from circulation.
In contrast, persistent IC formation oc-
curs in a variety of chronic disease states
and can result in unregulated, prolonged
FcgR signaling when defects in IC clear-
ance are also present. Chronic diseases
with ICs are often of autoimmune, neo-
plastic, or infectious etiologies and occur
when antibody is continuously produced,
either appropriately (as in infection) or
inappropriately (as in autoimmune and
some neoplastic diseases), which reacts
with pathogen or host antigens. In these
settings, unchecked IC-FcgR interactions
can culminate in hallmark sequelae of
inflammatory diseases such as glomeru-
lonephritis, vasculitis, arthritis, and bone
erosion.
In addition to these classic inflamma-
tory manifestations, persistent ICs can
contribute to a broad range of abnormal-
ities in innate and adaptive immunity,including elevated type 1 interferon (IFN)
and dysregulated B and T cell functions.
Elevated Type 1 IFN concentrations are
sustained, in part, through TLR signaling
following FcgR-mediated IC uptake; hy-
peractivation of immune cells can result,
contributing to loss of peripheral toler-
ance, including increased autoantibody
production as is classically seen in sys-
temic lupus erythematosis, HIV, and in
Lyme arthritis following Borrelia burgdor-
feri infection. Persistent elevation of type
1 IFN can also have broad immunosup-
pressive effects resulting from induction
of the anti-inflammatory cytokine inter-
leukin-10 (IL-10) and/or upregulation of
programmed cell death ligand 1, an inhib-
itory coreceptor for T lymphocytes (Ban-
chereau and Pascual, 2006). Persistent
ICs are also associated with dysfunctional
lymphocyte populations; B cell abnormal-
ities are perhaps best characterized in
humans in HIV infection and can include
polyclonal activation (including of autor-
eactive specificities), suppressed anti-
viral IgA responses, and delayed or ab-
sent production of neutralizing antibodies
(Moir and Fauci, 2009). T cell ‘‘exhaus-
tion’’ in IC disease, characterized by
loss of effector function, is present in
several chronic human viral infectionsFebruary 17, 2015 ª2015 Elsevier Inc. 213
Figure 1. Crosslinking of Activating FcgRs Is Required for IgG Effector Functions Such as
ADCC
(Left) Model for B cell depletion through administration of an anti-CD20mAb. Fc domains of anti-CD20 IgG
bound to B cells crosslink activating FcgRs on the effector cell, resulting in cytotoxicity.
(Right) Model for blocking of FcgRs in chronic LCMV infection. IC formed in LCMV could block activating
FcgRs, while not causing substantial receptor crosslinking, thus blocking IgG-mediated effector functions
such as ADCC.
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Previewsincluding HIV, HCV, and HBV. How anom-
alous IC-FcgR interactions contribute
to such global immune dysfunction is
a focus of interest since FcgRs are
relatively well characterized and can
be individually targeted for therapeutic
interventions.
The studies by Weiland et al. and
Yamada et al. used a chronic LCMV
mouse model to demonstrate that ICs
formed during infection could prevent
effector functions of exogenously admin-
istered monoclonal antibodies (mAbs)
whose activities are normally FcgR-
dependent. Interestingly, both groups
found that loss of FcgR-mediated effector
functions was likely due to competitive
inhibition by high amounts of IC formed
during infection (Figure 1). Weiland
et al. made the observation that several
depleting mAbs, including Rituximab, a
depleting anti-CD20 IgG, and an agonistic
anti-CD40 IgG, lost therapeutic activity
in the setting of chronic LCMV infection
with ICs. Yamada et al. observed that
depleting FcgR-mediated activity, as
well as FcgR effector functions required
for optimal control of viral infections,214 Immunity 42, February 17, 2015 ª2015 Eincluding ADCC and cross-priming of
CD8+ T cells, were inhibited by IC. The
observations in both papers might be
broadly relevant to observed cellular im-
pairments in chronic viral infections, ma-
lignancy, and autoimmune diseases.
The finding that FcgR-engagment by
exogenously administered mAbs could
be disrupted through competitive inhibi-
tion with IC is unexpected. IC diseases
are not generally associated with dec-
reased clinical effectiveness of therapeutic
mAbs—on the contrary, Rituximab shows
robust B cell-depleting activity in patients
with a variety of diseases in which ICs are
found. In addition, in animal models of
HIV infection, durable viral suppression
by exogenously administered neutralizing
HIV antibodies can be achieved and is
dependent on activating FcgR function
(Bournazos et al., 2014). The LCMV sys-
tem used in these reports might reveal a
previously unappreciated mechanism for
immune compromise through exceedingly
high amounts of ICs and, indeed, very high
IC concentrations might account for some
of the clinical variability observed in res-
ponse to mAb therapies.lsevier Inc.If high concentrations of ICs can have
an FcgR-blocking effect in humans, this
might help to explain immune abnormal-
ities common to many chronic IC dis-
eases. For example, that IC was found
by Weiland et al. to prevent activity of an
agonistic anti-CD40 mAb suggests spe-
cific inhibition of FcgRIIB interaction. The
inhibitory FcgRIIB is central to balanced
signaling that results in healthy immune
responses. On B cells, the inhibitory
FcgRIIB functions in maintenance of pe-
ripheral tolerance and maturation of anti-
body responses. On follicular dendritic
cells (FDC), FcgRIIB functions as a scaf-
fold for ICs on which germinal center
B cells are selected; disruption of FDC
IC-FcgRIIB interaction results in profound
diminution of B cell recall responses.
Thus, inhibition of normal IC-FcgRIIB
binding would be expected to manifest
clinically as impaired humoral immune ac-
tivity and, indeed, chronic diseases with
ICs are often associated with antibody re-
sponses that are diminished or lacking in
durability. Further studies will be required
to determine whether chronic ICs, per se,
might be involved in the ontogeny of
impaired humoral immunity.
Impaired IC-FcgR interactions could
also contribute to clinical variability in pro-
duction of a ‘‘vaccinal’’ effect following
Rituximab therapy for B cell lymphoma,
a neoplasm that can be associated with
rheumatoid arthritis (in which ICs are
found). The vaccinal effect is a phenome-
non thought to occur when Rituximab-B
cell complexes are taken up through acti-
vating FcgRs for cross presentation to
and activation of CD8+ T cells. This effec-
tively primes for amemory T cell response
that can prevent tumor recurrence for
years after Rituximab therapy (Abe`s
et al., 2010). Inhibition of activating FcgR
activity due to persistent ICs in circulation
could conceivably prevent this long-term
therapeutic effect of Rituximab treatment.
Variables that undoubtedly affect the
biological outcome of persistent ICs are
the activity of complement pathways
and the valency and IgG subclass compo-
sition of IC. Defects in early complement
proteins are associated with decreased
IC clearance, which can result in IC depo-
sition in organs such as kidney and lung
(Davies et al., 1992). Valency and IgG sub-
class composition of complexes might
have a role in determining whether ICs
engage or effectively block FcgRs. Small
Immunity
PreviewsICs, or ICs generated from IgG sub-
classes with low affinity for activating
FcgRs, might not crosslink these FcgRs
sufficiently to activate substantial signal
transduction, yet might act to obscure
FcgR binding domains. The ratio of anti-
gen:IgG present in circulation at any one
time will affect the valency of IC, with
lower antigen:IgG ratios resulting in larger
complexes and increased activating/in-
flammatory FcgR activity. This can be
demonstrated experimentally through
resolution of IC-mediated disease after
administration of excess antigen (Valdes
et al., 1969).
That chronic, high-level ICs might
diminish efficacy of therapeutic mAbs
provides further rationale for Fc domain
engineering of therapeutic antibodies.
Fc domain engineering can substantially
enhance affinity for specific FcgRs, thus
ensuring appropriate and optimal FcgR-
mediated effector activity and increas-
ing mAb potency. Many Fc-engineered
mAbs are currently in clinical trials. Obinu-
tuzumab, a recently approved anti-CD20
IgG optimized for activating FcgRIIIa bind-
ing, has demonstrated remarkable clinical
success in the treatment of CLL, extend-
ing median progression-free survival bymore than 10 months when compared
with Rituximab treatment (Goede et al.,
2014), an anti-CD20 antibody with an un-
modified IgG1 Fc. Fc domain engineering
is a promising strategy for therapeutic
mAbs andmight prove useful in novel vac-
cine strategies involving administration
of immune complexes optimized to elicit
enhanced antibody responses. The work
by Weiland et al. and Yamada et al. are
clinically relevant, with important implica-
tions for the pathogenesis of immune ab-
errations observed in chronic IC diseases.
Their findings should inform the design of
novel therapeutic antibodies.ACKNOWLEDGMENTS
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